Table 1.
CD80 expression by breast cancer cell line KS enhances its stimulatory capacity
| Breast cancer patient | Stimulator cellsa | |||
|---|---|---|---|---|
| KS | KS-mock | KS-CD80 | LAZ509 | |
| BCP1 | 2.3b | 3.3 | 78.4 | 770.0 |
| BCP2 | 0 | 0.1 | 78.4 | 263.8 |
| BCP3 | 0.1 | 0 | 0.3 | 1,148.0 |
| BCP4 | 0.5 | 0.8 | 326.8 | 1,521.6 |
| BCP5 | 2.9 | 1.5 | 73.0 | 2,376.0 |
| BCP6 | 1.6 | 0.7 | 25.8 | 58.7 |
| BCP7 | 0.2 | 0.1 | 34.7 | 231.6 |
| BCP8 | 2.0 | 1.7 | 84.0 | 31.0 |
| BCP9 | 0 | 1.2 | 25.0 | 317.0 |
| BCP10 | 0.1 | 0.1 | 22.0 | 57.0 |
| BCP11 | 0.3 | 2.0 | 3.0 | 108.0 |
| BCP12 | 1.0 | 0.5 | 5.0 | 59.0 |
| BCP13 | 0.3 | 1.0 | 17.0 | 61.0 |
| BCP14 | 3.1 | 2.8 | 1.5 | 24.1 |
| BCP15 | 7.7 | 6.4 | 11.1 | 99.7 |
aT cells of breast cancer patients were stimulated with the allogeneic KS cell line, its CD80-transfected variant, or a mock-transfectant (all IFN-γ-pretreated). The allogeneic B-cell line LAZ509 was included as a positive control
bProliferation of T cells was assessed by [3H]thymidine incorporation after 5 days of coculture. Proliferation rates were given as stimulative index (SI). For details see “Material and methods”